ClinicalTrialsFinder
RecruitingNCT07197723

Study of How People Make Decisions About Prostate Cancer Risk

Effect of Polygenic Risk Modifiers on Decisions of BRCA1/2 Mutation Carriers at Risk for Prostate Cancer

Sponsor

Memorial Sloan Kettering Cancer Center

Enrollment

150 participants

Start Date

Sep 25, 2025

Study Type

OBSERVATIONAL

Conditions

BRCA1/2Geneitic Testing

Summary

The purpose of this study is to learn how people with BRCA1/2 mutations respond to genetic risk modifier testing. The researchers will learn more about how people make choices about their health care, including about methods to screen for prostate cancer. Researchers are also doing this study to learn about how the genetic risk modifier test affects people's thoughts and feelings.

Eligibility

Sex: MALEMin Age: 45 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This study is examining how men with a BRCA1 or BRCA2 gene mutation make decisions about prostate cancer screening and risk management. These gene mutations increase the risk of several cancers. Researchers want to understand what factors influence their choices. **You may be eligible if...** - You are a man (assigned male sex at birth) aged 45–70 - You do NOT currently have prostate cancer - You have tested positive for a BRCA1 or BRCA2 gene mutation in a clinical lab - You can communicate in English **You may NOT be eligible if...** - You have already been diagnosed with prostate cancer - You have a major psychiatric illness or significant cognitive impairment - You cannot complete the study surveys in English Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

GENETICcheek (buccal) swab

swab sample in person or at home with a mailed test kit and will fill out a survey

OTHERAssessments

about 1 week, 6 months, and 12 months after getting the updated cancer risk assessment to complete additional surveys.

OTHERoptional collection of blood

for research testing

Locations(1)

Memorial Sloan Kettering Cancer Center

New York, New York, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07197723

Related Trials

Responses to Genetic Risk Modifier Testing Among Women With Pathogenic Variants in Breast Cancer Predisposition Genes

NCT033963417 locations